For research use only. Not for therapeutic Use.
SR18662 is a potent inhibitor of Krüppel-like factor five (KLF5) with an IC50 of 4.4 nM and an analogue of ML264 (HY-19994) with improved inhibitory potency against colorectal cancer cells. SR18662 can be used for the study of colorectal cancer[1].
SR18662 (0-10 μM; 24-72 hours) significantly reduces growth and proliferation of CRC cells as compared to treatment with vehicle control, ML264 (HY-19994). It shows improved efficacy in reducing viability of multiple CRC cell lines[1].SR18662 (10 μM; 24-72 hours) shows a significant increase in the number of apoptotic cells at both early and late states in DLD-1 and HCT116 cells[1].SR18662 (1 μM; 72 hours) reduces the expression of cyclins (cyclins E, A2, and B1) and components of MAPK (p-Erk) and WNT signaling pathways (p-GSK3 β) in cells[1].
SR18662 (intraperitoneal injection; 5-10 mg/kg; daily or twice daily; 5 days injection, days break, and 5 days) significantly reduces the growth of tumors in a mouse xenograft model[1].
Catalog Number | I045827 |
CAS Number | 2505001-62-5 |
Synonyms | (E)-3-(3,4-dichlorophenyl)-N-[2-(4-methylsulfonylpiperazin-1-yl)-2-oxoethyl]prop-2-enamide |
Molecular Formula | C16H19Cl2N3O4S |
Purity | ≥95% |
InChI | InChI=1S/C16H19Cl2N3O4S/c1-26(24,25)21-8-6-20(7-9-21)16(23)11-19-15(22)5-3-12-2-4-13(17)14(18)10-12/h2-5,10H,6-9,11H2,1H3,(H,19,22)/b5-3+ |
InChIKey | WUJBXFXHDUVSFM-HWKANZROSA-N |
SMILES | CS(=O)(=O)N1CCN(CC1)C(=O)CNC(=O)C=CC2=CC(=C(C=C2)Cl)Cl |
Reference | [1]. Julie Kim,et al.The Novel Small-Molecule SR18662 Efficiently Inhibits the Growth of Colorectal Cancer In Vitroand In Vivo.Mol Cancer Ther.2019 Nov;18(11):1973-1984. |